Compare StocksMRNA vs NOW

Moderna, Inc. (MRNA) vs ServiceNow, Inc. (NOW): Which Is the Better Buy in 2026?

As of 2026-06-19, MRNA is overvalued at $64, with a DCF intrinsic value of $6 and a margin of safety of -963%. NOW is overvalued at $95, with an intrinsic value of $85 and a margin of safety of -12%. Of the two, NOW has the wider margin of safety.

MRNA
Moderna, Inc.
$63.96
VS
NOW
ServiceNow, Inc.
$95.04

Rewards

MRNA
    NOW
    • Gross margin of 76.6% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
    • Free cash flow has grown at a 27.8% CAGR over the past 4 years, demonstrating strong earnings power growth.
    • Each dollar of retained earnings has created $3.22 of earning power — management is an exceptional capital allocator.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    NOW
    • Despite buyback spending, shares outstanding increased in 3 out of 3 years — stock-based compensation is offsetting repurchases.
    • FCF yield of 5.2% suggests reasonable valuation assuming continued moderate growth.
    • 6 insider sales totaling $2.7M with no purchases in the past 3 months — insiders are reducing their exposure.

    Key Valuation Metrics

    Learn more →
    MRNA
    NOW
    Valuation
    $-20.00M
    Free Cash Flow
    $5.11B
    -0.08%
    FCF Yield
    5.21%
    N/A
    Trailing P/E
    56.57
    -15.21
    Forward P/E
    18.91
    Quality & Moat
    -26.47%
    ROIC
    10.39%
    -36.56%
    ROE
    16.07%
    -69.89%
    Gross Margin
    76.56%
    N/A
    PEG Ratio
    0.98
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    Net cash
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    -0.95
    0.00%
    Dividend Yield
    0.00%
    MRNA: 2Ties: 1NOW: 6
    MRNANOW

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    NOW

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    NOW
    $16.65
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $4.90B
    Δ Market Cap
    +$81.66B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    962.8% Overvalued
    Price is 962.8% above estimated fair value
    Current Price: $63.96
    Fair Value: $6.02
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    NOW
    11.8% Overvalued
    Price is 11.8% above estimated fair value
    Current Price: $95.04
    Fair Value: $84.98
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    Requires positive FCF to compute implied growth rate.

    NOW

    What growth rate is the market pricing in at $95?

    +21.4%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +6.8%

    The market implies +21.4% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding +6.8%, reflecting heavy growth investment expected to generate future returns.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    NOW
    61/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    NOW
    -2.87
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
    No. of Institutional Holders1,044
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    NOW
    Insiders 0.2%Institutions 88.5%Retail & Other 11.4%
    No. of Institutional Holders3,080
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    NOW
    0
    Buys (3M)
    1
    Buys (12M)
    Total value (12M): $3.00M
    MCDERMOTT WILLIAM R
    Chief Executive Officer
    $3.00M
    @ $104.60 · 2026-02-27
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    3
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $11.57M
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    NOW
    6
    Sells (3M)
    40
    Sells (12M)
    Total value (12M): $24.71M
    BRIGGS TERESA
    Director
    $173,376
    @ $108.70 · 2026-05-28
    FIPPS PAUL
    Officer
    $103,238
    @ $98.51 · 2026-05-18
    CHAMBERLAIN PAUL EDWARD
    Director
    $130,845
    @ $87.23 · 2026-05-14
    SANDS ANITA M
    Director
    $1.48M
    @ $90.14 · 2026-05-14
    FIPPS PAUL
    Officer
    $13,661
    @ $90.47 · 2026-05-08
    CANNEY JACQUELINE P
    Officer
    $799,868
    @ $89.60 · 2026-04-24
    FIPPS PAUL
    Officer
    $376,142
    @ $101.77 · 2026-02-23
    FIPPS PAUL
    Officer
    $1.02M
    @ $105.93 · 2026-02-18
    MCBRIDE KEVIN THOMAS
    Officer
    $147,994
    @ $105.71 · 2026-02-13
    CHAMBERLAIN PAUL EDWARD
    Director
    $151,755
    @ $101.17 · 2026-02-12
    MASTANTUONO GINA
    President
    $352,750
    @ $850.00 · 2025-12-05
    CHAMBERLAIN PAUL EDWARD
    Director
    $242,400
    @ $808.00 · 2025-11-28
    MASTANTUONO GINA
    President
    $336,936
    @ $808.00 · 2025-11-28
    JACKSON LAWRENCE
    Director
    $214,708
    @ $810.22 · 2025-11-28
    CANNEY JACQUELINE P
    Officer
    $200,549
    @ $839.12 · 2025-11-18
    FIPPS PAUL
    Officer
    $249,353
    @ $817.55 · 2025-11-18
    ELMER RUSSELL S.
    General Counsel
    $160,155
    @ $838.51 · 2025-11-18
    TZITZON NICHOLAS
    Officer
    $431,736
    @ $827.08 · 2025-11-18
    MCBRIDE KEVIN THOMAS
    Officer
    $235,894
    @ $842.48 · 2025-11-14
    CANNEY JACQUELINE P
    Officer
    $56,257
    @ $852.38 · 2025-11-13
    ELMER RUSSELL S.
    General Counsel
    $52,848
    @ $852.39 · 2025-11-13
    CANNEY JACQUELINE P
    Officer
    $222,012
    @ $863.86 · 2025-11-10
    ELMER RUSSELL S.
    General Counsel
    $164,997
    @ $863.86 · 2025-11-10
    SANDS ANITA M
    Director
    $1.00M
    @ $915.11 · 2025-08-29
    MCDERMOTT WILLIAM R
    Chief Executive Officer
    $5.34M
    @ $916.63 · 2025-08-28
    FIPPS PAUL
    Officer
    $1.30M
    @ $895.32 · 2025-08-20
    ELMER RUSSELL S.
    General Counsel
    $1.50M
    @ $884.26 · 2025-08-20
    MCDERMOTT WILLIAM R
    Chief Executive Officer
    $1.43M
    @ $900.00 · 2025-08-19
    CANNEY JACQUELINE P
    Officer
    $1.35M
    @ $866.45 · 2025-08-18
    MASTANTUONO GINA
    President
    $1.53M
    @ $866.45 · 2025-08-18
    TZITZON NICHOLAS
    Officer
    $1.49M
    @ $866.45 · 2025-08-18
    MCBRIDE KEVIN THOMAS
    Officer
    $238,496
    @ $851.77 · 2025-08-15
    CHAMBERLAIN PAUL EDWARD
    Director
    $258,000
    @ $860.00 · 2025-08-14
    CANNEY JACQUELINE P
    Officer
    $57,658
    @ $860.57 · 2025-08-13
    MASTANTUONO GINA
    President
    $72,288
    @ $860.57 · 2025-08-13
    CANNEY JACQUELINE P
    Officer
    $225,746
    @ $878.39 · 2025-08-08
    MASTANTUONO GINA
    President
    $256,490
    @ $878.39 · 2025-08-08
    JACKSON LAWRENCE
    Director
    $749,805
    @ $990.50 · 2025-07-29
    CANNEY JACQUELINE P
    Officer
    $341,631
    @ $965.06 · 2025-07-16
    SANDS ANITA M
    Director
    $250,950
    @ $1050.00 · 2025-07-03
    MCBRIDE KEVIN THOMAS
    Officer
    $283,310
    @ $1011.82 · 2025-06-03
    SANDS ANITA M
    Director
    $250,267
    @ $1009.14 · 2025-06-02
    CANNEY JACQUELINE P
    Officer
    $147,900
    @ $1020.00 · 2025-05-30
    MCDERMOTT WILLIAM R
    Chief Executive Officer
    $2.07M
    @ $1012.01 · 2025-05-30
    TZITZON NICHOLAS
    Officer
    $1.19M
    @ $1020.00 · 2025-05-30
    SANDS ANITA M
    Director
    $433,825
    @ $1013.61 · 2025-05-27
    BRIGGS TERESA
    Director
    $216,913
    @ $1013.61 · 2025-05-27
    LUDDY FREDERIC B
    Director
    $428,000
    @ $1000.00 · 2025-05-23
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    NOW
    FearGreed
    😨Fear(25/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    NOW
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (25)
    View MRNA Full AnalysisView NOW Full Analysis

    Frequently Asked Questions: MRNA vs NOW

    Is Moderna, Inc. or ServiceNow, Inc. more undervalued in 2026?

    Based on our discounted cash flow model, NOW trades at a -11.8% margin of safety (intrinsic value $85 vs. price $95), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

    Which stock has a wider economic moat, Moderna, Inc. or ServiceNow, Inc.?

    NOW scores 61/100 (Narrow moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. NOW scores 8.4 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or ServiceNow, Inc.?

    ServiceNow, Inc. (NOW) generates a 5.2% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or ServiceNow, Inc.?

    NOW earns 10.4% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    MRNA vs NOW: Which Is the Better Buy in 2026? | SafetyMargin.io